Pitolisant (Wakix®/Ozawade®)
Narcolepsy
ApprovedActive
Key Facts
About Bioprojet SCR
Bioprojet is a long-established, private French biopharmaceutical firm with a core competency in small molecule drug discovery and development, particularly in neuroscience. The company has successfully transitioned discoveries into a commercial portfolio, including the flagship product Wakix® (pitolisant) for narcolepsy, and maintains an active R&D pipeline. With a human-scale, agile research model and international commercial partnerships, Bioprojet leverages its integrated research center near Rennes to pursue novel therapeutic targets, aiming to address significant unmet medical needs in neurology and psychiatry.
View full company profileOther Narcolepsy Drugs
| Drug | Company | Phase |
|---|---|---|
| Pitolisant Tablets | lupin | Approved (Tentative) |
| Sodium Oxybate (one-nightly) | D&A Pharma | Development |
| Narcolepsy Study | Science 37 | Phase 4 |